3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Expanded_access
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
3
Thyroid Neoplasms
2
Thoracic Neoplasms
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Neoplasms, Nerve Tissue
2
Neoplasms, Germ Cell and Embryonal
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lung Diseases
2
Head and Neck Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Medullary
2
Carcinoma, Bronchogenic
2
Carcinoma
2
Adenocarcinoma
2
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Solid Tumors
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors
1
Neoplasms, Glandular and Epithelial
1
Multiple Endocrine Neoplasia Type 2a
1
Locally Advanced Thyroid Gland Carcinoma
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Interventions
vandetanib
12
cabozantinib
8
selpercatinib
5
Sorafenib
5
Everolimus
5
Magnetic Resonance Spectroscopy
3
Capecitabine
3
sargramostim
2
pralsetinib
2
lutetium Lu 177 dotatate
2
lenvatinib
2
Trastuzumab
2
Temozolomide
2
Sunitinib
2
Specimen Handling
2
Octreotide
2
High-Energy Shock Waves
2
Gefitinib
2
Doxorubicin
2
yeast-CEA vaccine
1
veliparib
1
vatalanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
temsirolimus
1
tanespimycin
1
sacubitril and valsartan sodium hydrate drug combination
1
rovalpituzumab tesirine
1
ponatinib
1
pentetreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Medullary
×
pralsetinib
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA
NCT04760288
2024-01-05
AcceleRET-MTC
Hoffmann-La Roche
Phase 3
Withdrawn